The treatment will commence after completion of the initial screening. The study encompasses a total of 12 treatment naive patients with chronic hepatitis C virus genotype 1 infections and with a low viral load. The patients are divided into four dose groups and each patient will receive a total of four monthly vaccinations and then monitored for another six months.
The study will be conducted at two sites at the Karolinska University Hospital; at the Infectious Disease Clinic (Huddinge) and the Centre for Gastroenterology (Solna). The main purpose of the study is to show that the treatment is safe. The study will also show if the treatment boosts the host immune response to hepatitis C, as well as its effects on the virus replication.
Jan Nilsson, CEO of Tripep, said: “We are very pleased that enrolment for the first human study on the ChronVac-C vaccine has started as planned.”